We understand how important it is for you to evaluate your compound in inflammatory disease models that best mimic the human condition. By combining classical pharmacology studies with state-of-the-art imaging expertise, Charles River can aid in the development of new therapies for inflammation. In vivo studies are accompanied by preclinical imaging, tissue and plasma biomarker analysis, and immunological assays.
Inflammation models include:
- Rheumatoid arthritis
- Delayed-type hypersensitivity (paw and ear edema)
- LPS-induced cytokine release
- Inflammatory bowel disease
- Asthma and airway hyper-responsiveness
- Experimental allergic encephalitis
- T-cell dependent antibody response (TNP-OVA immunization)
- Thioglycollate-induced peritonitis
- Sponge granuloma
- Atherosclerosis
For more information about our inflammation models for pharmacology studies, please contact us at askcharlesriver@crl.com.
|
Inflammation, inflammatory disease research, pharmacology studies, Rheumatoid arthritis, Delayed-type hypersensitivity, paw edema, ear edema, LPS-induced cytokine release, Inflammatory bowel disease, Asthma, airway hyper-responsiveness, Experimental allergic encephalitis, T-cell dependent antibody response, TNP-OVA immunization, Thioglycollate-induced peritonitis, Sponge granuloma, Atherosclerosis
Pharmacology Studies | Inflammation | Charles River
By combining classical pharmacology studies with state-of-the-art imaging expertise, Charles River can aid in the development of new therapies for inflammation.